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Background: Histone acetylation/deacetylase process is one of the most studied epigenetic modifications. His-
tone deacetylase inhibitors (HDACis) have shown clinical benefits in haematological malignancies but failed
in solid tumours due to the lack of biomarker-driven stratification.
Methods: We perform integrative pharmaco-transcriptomic analysis by correlating drug response profiles of
five pan-HDACis with transcriptomes of solid cancer cell lines (n=659) to systematically identify generaliz-
able gene signatures associated with HDACis sensitivity and resistance. The established signatures are then
applied to identify cancer subtypes that are potentially sensitive or resistant to HDACis, and drugs that
enhance the efficacy of HDACis. Finally, the reproductivity of the established HDACis signatures is evaluated
by multiple independent drug response datasets and experimental assays.
Findings:We successfully delineate generalizable gene signatures predicting sensitivity (containing 46 genes)
and resistance (containing 53 genes) to all five HDACis, with their reproductivity confirmed by multiple
external sources and independent internal assays. Using the gene signatures, we identify low-grade glioma
harbouring isocitrate dehydrogenase 1/2 (IDH1/2) mutation and non-YAP1-driven subsets of small-cell lung
cancer (SCLC) that particularly benefit from HDACis monotherapy. Further, based on the resistance gene sig-
nature, we identify clinically-approved Dasatinib as a synthetic lethal drug with HDACi, synergizing in induc-
ing apoptosis and reactive oxygen species on a panel of SCLC. Finally, Dasatinib significantly enhances the
therapeutic efficacy of Vorinostat in SCLC xenografts.
Interpretation: Our work establishes robust gene signatures predicting HDACis sensitivity/resistance in solid
cancer and uncovers combined Dasatinib/HDACi as a synthetic lethal combination therapy for SCLC.
Funding: This work was supported by the National Natural Science Foundation of China (82072570 to F. Yao;
82002941 to B. Sun).
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Histone modifications, particularly histone acetylation/deacetyla-
tion, represent a major epigenetic regulatory process and play an
essential role in a number of human cancers. Histone deacetylation is
a critical regulator of gene transcription involving the removal of ace-
tyl groups and is regulated by a group of enzymes termed histonedeacetylases (HDACs). HDACs are divided into four classes: class I
(HDAC 1, 2, 3, and 8), II (IIa: HDAC 4, 5, 7, and 9; IIb: HDAC 6 and 10),
III (SIRT1, 2, 3, 4, 5, 6, and 7) and IV (HDAC11) [1]. HDACs also regu-
late the acetylation of a variety of non-histone proteins, substrates
through different mechanisms [2,3], resulting in multiple biological
consequences involved in cell cycle arrest, apoptosis, autophagy, and
generation of reactive oxygen species (ROS) [4,5].
Dysregulation of HDACs in multiple types of human cancer is
associated with poor prognosis [6], making these enzymes an impor-
tant therapeutic target [1]. Currently, most chemically-developed
HDACis are pan-HDACis rather than being HDAC class member-
Research in context
Evidence before this study
Histone acetylation/deacetylation represents a major epige-
netic regulatory process and plays an essential role in human
cancers. Upregulation of HDACs has been reported in several
human cancer types, making these regulative enzymes a very
interesting therapeutic target. However, HDAC inhibitors show
clinical success in the treatment of patients with haematologi-
cal malignancies, but not those with solid tumours leading to
the highly heterogeneous responsiveness. The major reason is
the lack of biomarkers to stratify patients for HDAC targeted
therapies.
Added value of this study
Our work systematically identified generalizable gene signa-
tures associated with HDACis sensitivity and resistance with
reproductivity. More importantly, based on the established sig-
natures, we identified non-YAP1-driven small-cell lung cancer
(SCLC) and brain tumours with IDH1/2 mutations as the cancer
subsets suitable for HDAC targeted therapies. Further, we iden-
tified that the effect of HDAC inhibitors in SCLC could be further
synergistically enhanced by combining clinically-approved
Dasatinib.
Implications of all the available evidence
Our findings may be instrumental for the precise management
of HDAC targeted therapies for a subset of patients with solid
tumours.
2 H. Yang et al. / EBioMedicine 69 (2021) 103457specific [7]. To date, four pan-HDACis, Vorinostat, Romidepsin, Beli-
nostat, and Panobinostat, have been approved by the Food and Drug
Administration for the treatment of haematological malignancies [7],
and show particular benefit in cutaneous T-cell lymphoma, but failed
to demonstrate therapeutic benefit in solid tumours. Additionally, as
single agents, HDACis have shown poor response duration with the
rapid development of therapy resistance [4]. Together, these data
suggest an urgent need to develop a biomarker-guided stratification
strategy, as well as evaluating the success of combinatorial therapy
aimed at improving the effectiveness of HDACis while delaying
highlighting the importance of combined therapy in delaying the
emergence of treatment resistance [7].
Dysregulated Hippo-YAP signalling pathway has been fre-
quently observed in cancer cells developing resistance to various
treatments, including drug compounds modulating epigenetic
process, e.g. BET [8] and HDAC inhibitors [9]. Hippo signalling
transduction converges on the LATS1/2-dependent phosphoryla-
tion of the transcriptional master YAP (Yes-associated protein,
encoded by YAP1) and its co-activator TAZ. Phosphorylation YAP/
TAZ by LATS kinases promotes their translocation from the
nucleus to the cytoplasm, where it is sequestered by 14-3-3 pro-
teins, leading to subsequently ubiquitin-mediated proteolysis. Fol-
lowing the inactivation of the Hippo pathway, unphosphorylated
YAP and its co-activator TAZ translocate to the nucleus to control
the expression of their downstream target genes, which have
been shown to control cell proliferation and inhibit cell death,
underpinning the tumorigenic potential of YAP/TAZ. Additionally,
we and other groups have demonstrated a close link between
the YAP activity and the effect of BCR/ABL-SRC inhibitors, e.g.
Dasatinib [10-13]. Interestingly, multiple lines of evidence show
that HDACis can overcome resistance to BCR/ABL-SRC inhibitors
[14-16]. Collectively, the above evidence suggests a potentiallyreciprocal compensation between HDAC- and YAP-regulated sig-
nalling pathways.
In this study, we sought to systematically delineate the gene net-
works correlated with HDACi sensitivity and resistance in solid
tumour cells to identify the responsive biomarkers to HDAC targeted
therapies. To generalize the results and minimize potential off-target
effects, multiple clinically-approved HDACis, namely Vorinostat, Enti-
nostat, and Panobinostat, and clinically-advanced HDACis Belinostat
and Apicidin, were integrated. Based on comprehensive correlation
analysis of drug response profiles with genome-wide transcriptomics
across solid cancer cell lines (n=659), we established HDACis sensi-
tive and resistant signatures, which leads to identifying cancer sub-
types that are suitable for HDACis-based therapy. More importantly,
the integration of the HDACis resistant signature informed Dasatinib
as an ideally synergistic combination treatment to enhance the effect
of HDACis.
2. Methods
2.1. Cell culture, drug treatment
SCLC (DMS-114 [ATCC Cat# CRL-2066, RRID:CVCL_1174], DMS-53
[ATCC Cat# CRL-2062, RRID:CVCL_1177], GLC-15 [KCB Cat# KCB
90028YJ, RRID:CVCL_6904]) and NSCLC cell lines (H1650 [KCLB Cat#
91650, RRID:CVCL_1483], H4006 [ATCC Cat# CRL-2871, RRID:
CVCL_1269], H1792 [ATCC Cat# CRL-5895, RRID:CVCL_1495], H1944
[ATCC Cat# CRL-5907, RRID:CVCL_1508]) were cultured in RPMI-
1640 (Sigma-Aldrich, R8758), supplemented with 10% fetal bovine
serum (FBS) (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich)
at 37 °C in a humid incubator with 5% CO2. All cancer cell lines were
obtained from ATCC (American Type Culture Collection, Manassas,
VA, USA) and have been authenticated using STR profiling within the
last three years and are confirmed free from mycoplasma contamina-
tion. Clinically-approved Dasatinib (Cat. #S1021), Vorinostat (Cat.
#S1047), Bosutinib (Cat. #S1014), and Panobinostat (Cat. #S1030)
were purchased from Selleck (China).
2.2. Ethics statements for animal experiments
All animal studies were conducted according to the guidelines for
the care and use of laboratory animals and were approved
(#KS20210429) by the Institutional Animal Care and Use Committee
of Shanghai Institute of Nutrition and Health.
2.3. Cell viability assay and quantitative analysis of drug synergy
Cells were seeded in 96-well plates (1,000  1,500 cells/well), and
treated with DMSO (control), Dasatinib or Bosutinib (dual Src/Abl
inhibitor inhibitors), HDAC inhibitors (Vorinostat and Panobinostat),
alone or in combination for 96 h, and cell viability was quantified by
the Acid Phosphatase Assay Kit (ab83367; Abcam, Cambridge, UK)
according to the manufacturer’s protocol. The median inhibitory con-
centration (IC50) was calculated using GraphPad Prism 7. Drug syner-
gism was determined by CompuSyn software, which is based on the
median-effect principle and the combination indexisobologram
theorem [17-20]. CompuSyn software generates fraction affected (Fa)
and combination index (CI) values. CI<1.0, synergism; CI = 1.0, addi-
tive effects; CI> 1.0, antagonism.
2.4. Flow cytometry-based measurement of apoptosis, lipid ROS, and
cell cycle
SCLC cells (GLC-15) treated for 24 h with DMSO (control), Dasati-
nib (0.5 mM), and Vorinostat (HDAC inhibitor, 1 mM), alone and in
combination, were subsequently subjected for flow cytometry-based
measurement of apoptosis, lipid ROS, and cell cycle, respectively.
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Annexin V-FITC/PI apoptosis detection kit (Cat. #A211-01; Vazyme
Biotech Co., Ltd) according to the manufacturer’s instruction and as
previously described [12].
Concerning the lipid ROS analysis, the cells were stained (20 min,
37°C) with 2.5 mM of BODIPYTM 581/591 C11 (Invitrogen, D3861).
After washing with PBS, the cells were harvested and resuspended in
2% FBS-containing PBS.
Regarding the cell cycle analysis, cells were washed twice with
cold PBS and resuspended in PBS to get single-cell suspensions,
which were then dropped in ice-cold 70% ethanol for at least 2 hours.
After that, cells were stained with 1 mg/ml DAPI. For the details of
cell cycle analysis, a protocol available at https://flowcytometry-
embl.de/wp-content/uploads/2016/12/DAPIstaining-.pdf was used.
Subsequently, the cells were subjected to flow cytometry analysis
performed by BD LSRII, with data analysis (n=3 biological repeats)
using FlowJo v10.
2.6. Animal experiments
Age- and gender-matched NSG (NOD-SCID IL2Rgnull (IMSR Cat#
NM-NSG-012, RRID:IMSR_NM-NSG-012)) mice (n=5 each group)
were used for animal experiments with human small-cell lung cancer
cell line (GLC-15). For GLC-15 xenografts, tumour cells mixed with
Matrigel (356231; Corning) were subcutaneously inoculated in left
and right flanks (2 million/injection). Treatment was initiated when
tumor volume was around 100 mm3, and drugs (Vorinostat,
25 mg/kg, i.p.; Dasatinib, 15 mg/kg, i.p.) were prepared in the follow-
ing solvent: 2% DMSO + 40% PEG300 + 5% Tween-80 + 53% saline
administered 7 days/week*2 weeks. Tumour size/volume was mea-
sured every 3 days and calculated by the formula: (D£ d2)/2, where
“D” refers to the long tumour diameter and “d” the short one [18].
2.7. Public databases
Processed and standardized drug screening and genome-wide
gene expression data across a set of small-molecule compounds
(n=481) and solid cancer cell lines (n=659) from the supplementary
files (Supplementary Data Set 36) of a published study [21] were
downloaded for reanalysis. Correlation data across all 481 small mol-
ecules against individual transcriptomes that are significantly corre-
lated with response to at least one small molecule were included for
analysis [21]. The area under the curve (AUC), determined by fitted
concentration-response curves (2-fold dilution, over a 16-point con-
centration range), is used as a measure of sensitivity. Fisher's z-trans-
formation was applied to the correlation coefficients (Pearson) to
adjust for (normalize) variations in cancer cell line number across
small molecules and contexts [21], with significance corresponding
to a Bonferroni-corrected, two-tailed distribution with family-wise
error-rate a < 0.025 in each tail (|z| > 5.83). The frequency of signifi-
cant compoundtarget pairs were compared to all compoundtran-
script pairs exceeding this |z| threshold using a chi-squared test [21].
For validation analysis, the drug response profiles to different HDACis
from independent CTRP (V1) (https://portals.broadinstitute.org/ctrp.
v1/) [22], GDSC (Genomics of Drug Sensitivity in Cancer, https://
www.cancerrxgene.org/) dataset and NCI-60 cancer cell cohort
(n=41, 19 hematopoietic/lymphoid-derived cancer cell lines were
excluded) [23] were employed. The normalized RNA-sequencing
data of identified genes across The Cancer Genome Atlas (TCGA) Pan-
cancer cohort was downloaded from cBioPortal (https://www.cbio
portal.org/). Normalized transcriptomic data of cancer cell lines were
downloaded from Cancer Cell Line Encyclopedia (CCLE) project
(https://portals.broadinstitute.org/ccle). The protein level of YAP and
TAZ across cancer cell lines was extracted from the normalized level
3 data of reverse phase protein array (RPPA) were downloaded from
The Cancer Proteome Atlas (TCPA) database (https://tcpaportal.org/tcpa/) of the TCGA project [24]. DNA methylation profiles across the
TCGA pan-cancer cohort were downloaded from the UCSC Xena por-
tal (https://xena.ucsc.edu/). Protein interactions and pathway enrich-
ment analyses were based on STRING databases (version 11.0;
https://string-db.org/). Characterization of SCLC subtypes was based
on a previously curated public resource [25].
2.8. Immune subtype models
Immune subtype models (C1-C6) were based on a previous study
[26]. The genes contained in each signature were evaluated using
model-based clustering by the “mclust” R package. Each sample was
finally to be grouped based on its predominance with the C1-C6 sig-
nature. R software (version 3.6.3) was used for statistical analyses
and data presentation.
2.9. Gene signature scores
2.9.1. HDACis sensitive and resistant signature score
HDACis sensitive and resistant signature scores were calcu-
lated by summarizing the Z-normalized log2RSEM (RNA-Seq by
Expectation-Maximization, downloaded from cBioPortal (https://
www.cbioportal.org/)) of the expression data for the genes in the
HDACis sensitive and resistant signatures, based on the RNA-
sequencing data of TCGA pan-solid patients` tumour and pan-
solid cancer cell lines from CCLE. Gene signature sore calculation:
after scaling the genes expression value by Apply function in R, a
sum of gene expression of the selected genes within the HDACi
sensitivity and resistance gene signatures was then summarised
as a single score for each sample.
2.9.2. YAP-TAZ target gene signature score
A curated 22-gene YAP-TAZ target gene signature (MYOF,
AMOTL2, LATS2, CTGF, CYR61, ANKRD1, ASAP1, AXL, F3, IGFBP3,
CRIM1, FJX1, FOXF2, GADD45A, CCDC80, NT5E, DOCK5, PTPN14, ARH-
GEF17, NUAK2, TGFB2, RBMS3) were utilized based on a previous
study [27], which used published RNA-sequencing and ChIP-
sequencing data across various cancer types. YAP-TAZ target score
was calculated by summarizing the Z-normalized log2RSEM (RNA-
Seq by Expectation-Maximization) of the expression data for the 22
curated YAP/TAZ downstream transcription target genes, based on
the TCGA MPM RNA-sequencing data.
2.10. Survival analysis
Survival analysis was performed using “survminer” and “survival”
R packages. Tumour samples within the TCGA Pan-cancer, LGG, and
MESO cohorts were divided into two groups, based on the best-
separation cut-off value of indicated genes to plot the KaplanMeier
survival curves.
2.11. Statistical analysis
Data were presented as mean§ s.d., with the indicated sample
size (n) representing biological replicates. Data analysis was per-
formed by GraphPad Prism 7 (GraphPad Software, Inc., San Diego,
CA, USA). The group size was determined based on preliminary
experiments but no statistical method was used to predetermine
sample size. Group allocation was performed in a blinded man-
ner. Gene expression and survival data derived from the public
database, as well as the correlation coefficient (Pearson), were
analyzed using R (version 3.6.3) [28]. Statistical significance was
determined by one-way/two-way analysis of variance (ANOVA),
Bonferroni’s multiple comparison test, and Student’s t-test using
GraphPad Prism 8, unless otherwise indicated. P<0.05 was con-
sidered statistically significant.
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3. Results
3.1. Systematic correlation analysis identifies common gene signatures
predicting the sensitivity and resistance to different pan-HDAC inhibitors
To systematically identify common gene signatures that predict
HDACi response, we correlated the sensitivity profiling of five differ-
ent HDACis (Vorinostat, Entinostat, Panobinostat, Belinostat, and Api-
cidin) against the transcriptomes of a cohort of pan-solid cancer cell
lines (n=659), based on a previously curated small-molecule com-
pound library screen dataset (Fig. 1A) [21]. The results revealed two
gene signatures that were significantly correlated (empirical p-value
< 0.05), positively or negatively, with the area under the curve
(AUC), a measure of drug sensitivity determined by fitted concentra-
tion-response curves, of all five HDACis (Fig. 1BD; Suppl. Table 1).
Of note, the positively correlated genes indicate that higher gene
expression correlates with a higher AUC value of HDACis and is resis-
tant to HDACis. In contrast, the negatively correlated genes indicate
that higher gene expression correlates with lower AUC value of HDA-
Cis and are sensitive to HDACis. Thus, we defined the positively corre-
lated genes as HDACis resistant signature, containing 53 genes, and
the negatively correlated genes as HDACis sensitive signature, con-
taining 46 genes (Fig. 1D).
3.2. Validity of the established HDACis sensitivity and resistance gene
signatures
To confirm the reliability and validity of our established gene sig-
natures, we applied them to an independent cohort GDSC (Genomics
of Drug Sensitivity in Cancer, https://www.cancerrxgene.org/), which
provides sensitivity data of hundreds of drug compounds, including
various clinically-approved HDACis, e.g. Vorinostat, Entinostat, and
Panobinostat, assayed on hundreds of cancer cell lines from CCLE
(Cancer Cell Line Encyclopedia) cohort. We first calculated HDACi
sensitive and resistance gene signature scores across pan-solid cancer
cell lines (Suppl. Table 2), which were then merged with the drug
sensitivity profiles from GDSC. The results showed that the AUC val-
ues of the HDACis Vorinostat, Entinostat, and Panobinostat were all
significantly negatively correlated with the sensitive gene signature
score (Fig. 2A), and positively correlated with the resistant gene sig-
nature score (Fig. 2B), confirming the reliability and validity of our
established HDACis signatures. Additionally, we applied the HDACis
signatures to a second independent NCI-60 cell line cohort consisting
of 41 solid cancer cell lines treated with Vorinostat. The results con-
firmed a significant correlation between the HDACis signatures and
the drug effects of Vorinostat (Fig. 2C).
3.3. The HDACis sensitivity and resistance gene signatures facilitate the
identification of cancer subtypes vulnerable to HDACis
Next, we applied HDACis sensitivity and resistance gene signa-
tures to the cancer cell line cohort to identify cancer subtypes that
are potentially vulnerable to HDACi. The results showed that cancer
cells originating from the neuronal system, small intestine, and bone
display the highest HDACi sensitive score and lowest resistant score
(Fig. 2D), suggesting that cancer cells with these lineages are more
likely to be sensitive to HDACi treatment. By contrast, cancer cells
originating from the pleural tissue exhibit the highest HDACi resis-
tant and low HDACi sensitive signature score, indicating that pleuralmesothelioma (MESO) cells are generally resistant to HDACis
(Fig. 2D). Of note, there is a wide distribution of HDACi sensitivity
and resistance scores across lung cancer cells (Fig. 2D), implying that
response to HDACis in these lineage-derived tumours is highly het-
erogeneous. Interestingly, the top 50 cell lines with high HDACi sensi-
tive scores were mainly derived from small-cell lung cancer (SCLC)
(Suppl. Fig. 1A). In addition, SCLC has a significantly higher HDACi
sensitive score but a lower resistant score compared with non-SCLC
(NSCLC) (Fig. 2E). In support of this, mining the data source from
Basu, A. et al. [22] showed that SCLC is more sensitive to Vorinostat,
compared with NSCLC (Fig. 2F). Along these lines, IC50 of the four
HDACis is much lower for SCLC compared with NSCLC based on the
independent GDSC cohort (Fig. 2G), which was further experimen-
tally validated by cell viability assay using 3 SCLC and 3 NSCLC cell
lines in response to the clinically-approved HDACi Vorinostat
(Fig. 2H). Along the same line, Crisanti, et al. measured the IC50 value
of a panel of thoracic cancer cell lines, including NSCLC, SCLC and
MESO, in response to Panobinostat, demonstrating that SCLC cells
display the highest sensitivity, whereas MESO cells exhibit the most
resistance to HDACi Panobinostat [29]. Taken together, these results
suggest that HDACi may represent a promising treatment for SCLC
cells. Of important note, SCLC can be broadly divided into 4 molecular
subtypes by differential expression of four key transcription regula-
tors: achaete-scute homolog 1 (ASCL1), neurogenic differentiation
factor 1 (NEUROD1), yes-associated protein 1 (YAP1), and POU class 2
homeobox 3 (POU2F3) [30]. We further found that only YAP1 expres-
sion is significantly correlated with the HDACi sensitive (negatively)
and resistant (positively) signatures (Suppl. Fig. 1B), suggesting that
the YAP1-driven SCLC subtype may be resistant to HDACi. In support
of this, the YAP1-driven SCLC subtype is more resistant to HDACis,
compared with other SCLC subtypes, as indicated by significantly
higher AUC value of YAP1-driven SCLC cells in response to the HDA-
Cis Entinostat and Vorinostat (Fig. 2I). Additionally, using the previ-
ously curated YAP-TAZ target score that reflects the activity of the
dysregulated Hipp-YAP pathway [27], we observed a strong negative
correlation between HDACi sensitivity and YAP-TAZ target signature
scores in cancer cell lines from the CCLE (Suppl. Fig. 2A).
In addition to solid cancer cell lines, we also applied the estab-
lished HDACi signatures to Pan-cancer patient samples provided by
The Cancer Genome Atlas (TCGA) project. Of note, the TCGA does not
contain SCLC samples, mainly because most SCLC patients are diag-
nosed by fine-needle aspiration that leads to a lack of readily accessi-
ble and adequate tumour tissue. Clinically, HDACi sensitive and
resistant signatures are significantly negatively correlated (Suppl.
Figure 1B, C). More importantly, in line with the observations on cell
lines (Fig. 2D), patient samples from the neuronal system display the
highest HDACi sensitive and lowest HDACi resistant signatures,
whereas MESO samples exhibit the highest HDACi resistant signature
(Fig. 3A, B). Also, there is a significantly negative correlation between
HDACi sensitivity and YAP-TAZ target signature scores across low-
grade glioma (LGG) and glioblastoma (GBM) tumours (Suppl. Fig.
2B). Notably, genes negatively regulating the Hippo-YAP signalling
pathway (e.g., NF2, LATS1/2) are mostly observed in MESO tumours
(Suppl. Fig. 2C) [11], and activation of YAP oncoprotein, the terminal
effector of the Hippo pathway, has been reported in more than 70%
of MESO samples. Accordingly, MESO tumours display the highest
YAP-TAZ target score across TCGA pan-solid tumour cohorts (Suppl.
Fig. 2D). Given that the YAP signalling pathway correlates with the
resistance to HDACis (Suppl. Figure 1B, 2A; Fig. 2H), these multiple
lines of evidence support the exclusion of MESO as a potential
tumour type for HDACi monotherapy, highlighting the failure of a
previous phase III clinical trial investigating Vorinostat in patients
with advanced MESO [31].
It is well-known that mutations in isocitrate dehydrogenase 1 or 2
(IDH1/2), which results in the production of the oncometabolite 2-
hydroxglutarate (2-HG), an inhibitor of a-ketoglutarate-dependent
Fig. 1. Systematic correlation identifies generalized gene signatures predictive of therapeutic response to HDACis. A, Schematic model shows the pharmacogenomic analysis that
integrates transcriptomic data and drug response profiles across pan-solid cancer cell lines (n=659). B-D, Generalized HDACis sensitive (in blue, left in B-D) and resistant (in red,
right in B-D) signatures were established based on five HDAC inhibitors (B). Pearson correlation was performed, and genome-wide transcriptomes were included. Bonferroni-cor-
rected significance cutoff of |z| > 5.83, representing a two-tailed distribution with family-wise error-rate a < 0.025 in each tail, was used.
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Fig. 2. Generalized HDACis gene signatures reveal SCLC as potential subsets for therapeutic response to HDACis. A-B, An independent data cohort validating the correlation of HDA-
Cis sensitive (A) and resistant (B) signatures with the AUC (area under the curve) values of three HDACis (Vorinostat, Panobinostat, and Entinostat). Drug response profiles were
downloaded from the GDSC (Genomics of Drug Sensitivity in Cancer; https://www.cancerrxgene.org/) database. C, An independent NCI-60 data cohort validating the correlation of
HDACis sensitive (left) and resistant (right) signatures with log10 [GI50(molar)] of Vorinostat. Drug response profiles were downloaded from CellMinerCBD (version 1.2) (https://
discover.nci.nih.gov/cellminercdb/), and then merged with the gene expression array of the tested cancer cell lines. D, Prospective analysis of HDACis sensitive (upper panel) and
resistant (lower panel) signature scores across CCLE (Cancer Cell Line Encyclopedia) pan-solid cancer lines. HDACis sensitive and resistant signature scores were calculated by sum-
marizing the Z-normalized log2RSEM (RNA-Seq by Expectation-Maximization) of the expression data for the genes in the HDACis sensitive and resistant signatures, based on the
RNA-sequencing data of pan-solid cancer cell lines from CCLE. E, Significant difference (by Welch’s t-test) of HDACis sensitive (upper panel) and resistant (lower panel) signature
scores between small cell lung cancer (SCLC) and NSCLC cells. F, Cancer cells with high sensitivity (in red) to HDACi Vorinostat are significantly enriched for SCLC. Data were from
Basu A, et al. Cell (2013). G, Violin plots showing that SCLC cells are more sensitive to four HDACis reflected by the IC50 values, compared with NSCLC cells. H, Experimental valida-
tion of the differential sensitivity (reflected by IC50 value) of SCLC and NSCLC cells in response to HDACi Vorinostat. A significant difference was calculated by Welch’s t-test. **p <
0.01 (by Welch’s t-test). I, Independent datasets CellMiner-SCLC validating the association of non-YAP1-driven SCLC with therapeutic responses to two clinically-approved HDACis.
Data were from a curated public dataset (https://discover.nci.nih.gov/SclcCellMinerCDB/).
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Fig. 3. Generalized HDACis gene signatures reveal IDH1/2-mutant LGG as potential subsets for therapeutic response to HDACis. A-B, Prospective analysis of HDACis sensitive (A) and
resistant (B) signature scores across TCGA pan-solid cancer cohort. C, Significant difference (byWelch’s t-test) of HDACis sensitive signature score between IDH1/2-mutant (mut) and
wild-type (WT) LGG (low-grade glioma). D, Significant difference (by Welch’s t-test) in the sensitivity (reflected by IC50 [median inhibitory concentration (IC50)] value) of IDH1/2-
mutant (mut) and -wildtype (WT) solid cancer cells in response to two HDACis (Vorinostat, Belinostat). E-F, Kaplan-Meier survival analyses of pan-solid cancer (left in E; upper in
F), LGG (middle in E and F), and MESO (right in E; lower in F) stratified by the HDACis resistant gene signatures.
H. Yang et al. / EBioMedicine 69 (2021) 103457 7DNA demethylases, are the most common genetic alterations in gli-
oma [32]. Interestingly, we observed that IDH1/2 mutations were sig-
nificantly associated with high HDACi sensitive and low resistant
scores (Fig. 3C), suggesting that IDH1/2-mutant tumours are likely to
be more sensitive to HDACis. Supporting our findings, IDH1/2-mutant
solid cancer cells have significantly lower IC50 values compared with
wild-type (WT) in response to HDACis Vorinostat and Belinostat,
based on an independent GDSC data cohort (Fig. 3D). It was recentlyreported that IDH-mutant GBM displays higher sensitivity to the
HDACi panobinostat, compared with IDH-WT GBM [33]. Furthermore,
the HDACi resistant signature predicts a poor prognosis in terms of
overall survival (OS) and progression-free survival (PFS) in pan-solid
cancer types, LGG (highest HDACi sensitive signature), and MESO
(high HDACi resistant signature) (Fig. 3E, F). Given the role of IDH1/2
in regulating DNA methylation profiles, we sought to know whether
IDH1/2 mutations were associated with altered DNA methylation
8 H. Yang et al. / EBioMedicine 69 (2021) 103457levels in tumours. Our analysis showed that overall, DNA methylation
profiles of gene sets in the HDACi sensitive and resistant signatures
across TCGA pan-cancer patient cohort displayed an agreement with
the transcriptomic data (Fig. 3A, B; Suppl. Fig. 3A, 3B). For instance,
LGG tumours have the lowest transcriptomic level and highest DNA
methylation level in terms of the HDACi resistant gene signature
(Suppl. Fig. 3A). Besides, compared with MESO that has the highest
HDACi resistant signature score (Fig. 3B), LGG tumours exhibit signif-
icantly higher DNA methylation level of the HDACi resistant genes
(Suppl. Fig. 3B).
3.4. Identifying Dasatinib as a synergistic combination treatment with
HDACi
The efficacy of HDACi treatment as a monotherapy is not durable,
and resistance is common in response to HDACi treatment. Thus, it is
critical to identify additional targets to enhance the efficacy of HDACi
treatment.
The genes in the established HDACi resistant signature represent
potential effectors that mediate the resistance to HDACi targets, thus
leading to the assumption that targeting these genes might sensitize
cancer cells to HDAC targeted therapy. Next, we sought to identify
drug candidates whose effects correlated with the expression of
these genes. Through individually correlating the 53 genes of the
HDACi resistant signature (Fig. 1D) with the drug compounds in the
library, we observed that 38 of 53 (71.7%) genes whose higher
expression significantly correlate with lower AUC values of Dasatinib
(Fig. 4; Suppl. Figure 4), suggesting cancer cells with high expression
of these HDACi resistant genes are more sensitive to Dasatinib treat-
ment. These data suggest that combining BCR/ABL-SRC inhibitor
Dasatinib with HDACis may augment the effect of HDACis while help-
ing overcome resistance. Since YAP1 expression is highly correlated
with HDACi sensitivity (negatively) and resistance (positively) signa-
tures (Suppl. Figure 1B), we further correlated the AUC values of the
above drug compounds library with the protein level of YAP and TAZ
(a co-activator of YAP) across cancer cell lines, demonstrating Dasati-
nib as one of the most significantly negatively (sensitive) correlated
drugs, while Vorinostat as the most positively (resistant) correlated
drugs (Fig. 5A). These data suggest that cancer cells with activated
YAP are more sensitive to Dasatinib treatment but resistant to Vori-
nostat. In support of this, previous evidence demonstrated that
tumours with YAP activation display high sensitivity to Dasatinib
[10-13]. Further, in an independent GDSC drug sensitivity dataset, we
observed a significant negative correlation between the effect of
Dasatinib and HDACis on solid cancer cell lines (Suppl. Figure 5). Col-
lectively, these data indicate a reciprocal interplay between YAP- and
HDAC-involved signalling pathways. As a consequence, combined
HDACi and dasatinib therapies are likely to broadly inhibit both YAP-
and non-YAP-driven tumours, particularly in SCLC tumours (Fig. 5B).
The above evidence reveals the SCLC cells are highly primed for
HDACi treatment. To validate this, we treated three SCLC cells with
Vorinostat and Dasatinib, alone or in combination, which showed
that the combination treatment synergistically inhibited all tested
SCLC cell lines (Fig. 5C, 5D). To exclude the potential off-target effect
of Vorinostat (HDACi) and Dasatinib (SRC/ABLi), we tested one other
clinically-approved HDACi (Panobinostat) and SRC/ABLi (Bosutinib)
in the experimental system, which recapitulated our finds with Vori-
nostat and Dasatinib (Suppl. Figure 6A, 6B), confirming the syner-
gism between HDACi and SRC/ABLi. We and other groups previously
established the link of the effect of HDACi with apoptosis, elevated
ROS level, and cell cycle arrest [5,12,34,35]. Flow cytometry-based
analyses showed that combined Vorinostat and Dasatinib signifi-
cantly induced apoptosis and elevated ROS level compared with Vori-
nostat or Dasatinib treatment alone (Fig. 6A). More importantly, the
addition of the ROS scanger N-Acetylcysteine (2.5 mM) rescued the
inhibitory effect of the combination treatment (Fig. 6B). Additionally,HDACi alone mainly induced cell cycle arrest at the G2/M phase,
while Dasatinib alone predominantly arrested the cells at the G1
phase (Fig. 6C). Together, these data suggest that the combination
treatment exerts multiple effects on SCLC cells.3.5. Dasatinib promotes the therapeutic efficacy of Vorinostat in SCLC
tumour xenografts
We further investigated the therapeutic potential of combined
Dasatinib and Vorinostat for treating SCLC tumours in vivo. In this
preclinical model, we observed that Dasatinib significantly enhanced
the therapeutic efficacy of Vorinostat in SCLC xenografts (Fig. 7A, 7B).4. Discussion
HDACs are promising therapeutic targets and the development of
HDAC inhibitors is a hot topic in the treatment of cancer [7]. How-
ever, the treatment response to HDACis is highly heterogeneous [36],
and identifying the right subset candidates for HDACis-based therapy
remains a major challenge in solid tumours, despite the demon-
strated effect in haematological tumours. Exacerbating this dilemma
is the rapid development of resistance to HDACi treatment [4,37,38].
In this study, common HDACis sensitive and resistance signatures
were established by integrated pharmacogenomics of five HDACis,
which showed the robustness to identify two patient subsets for
HDACis monotherapy: IDH1/2-mutant LGG and non-YAP1-featured
SCLC. More importantly, we further identified Dasatinib, which pref-
erentially inhibits cancer cells with YAP activation, as an ideal tar-
geted therapy to synergistically enhance the efficacy of HDACi in
SCLC.
4.1. HDACis response signatures
Histone acetylation/deacetylation is one of the most widely inves-
tigated epigenetic processes. HDACs regulate the acetylation of a
variety of histone and nonhistone proteins, regulating the transcrip-
tion of diverse genes involved in cell proliferation, survival, differen-
tiation, and tumour immunity [39-41]; however, the exact molecular
mechanism affecting the efficacy currently remains unclear [38],
despite the successful applicability of HDACis for treatment of hae-
matological tumours.
Few studies have investigated the molecular biomarkers to pre-
dict the therapeutic responses to HDACi in cancer. Thus, clinical trials
have been largely based on unselected patients for HDACis treatment,
leading to their repeated failures [4,38]. Given the pleiotropic but
heterogeneous effects of HDACis on cancer cells, it becomes critical to
identify the biomarkers for their true therapeutic benefits in cancer.
In this study, we for the first time established generalized gene signa-
tures to identify cancer subsets that are potentially sensitive to HDA-
Cis. Intriguingly, we found that IDH1/2, which is frequently mutated
in LGG, has a high HDACis sensitive signature, and solid cancer cells
with IDH1/2 mutation display a high sensitivity to two clinically-
approved HDACis, compared with WT IDH1/2. In support of this
Zhang, et al. recently demonstrated that in leukaemia harbouring
mutated IDH1/2, which is a frequent event and plays a key role in
its pathogenesis, HDACis rapidly reversed the imbalance of
H3K9 methylation/acetylation in diseased hematopoietic stem and
progenitor cells, which significantly reduced the leukemic burden
[42]. The evidence from this study reveals new therapeutic opportu-
nities for leukaemia patients carrying IDH1/2 mutations. Thus, HDA-
Cis may be also a promising treatment in solid tumours, particularly
LGG and GBM that are predominantly characterized with IDH1/2
mutations [43], which has been recently reported in an abstract pub-
lication [33] and thus worths further pursuit in the future design of
clinical trials.
Fig. 4. Genes in the HDACis resistant signature correlate with the sensitivity to Dasatinib. Box-and-whisker plots show the extent of correlation between cytotoxic effects (reflected
by the area under the curve [AUC] value) of drug compounds in the library (n=481) and expression level of genes in the HDACi resistant signature. The y-axis indicates z scored Pear-
son’s correlation coefficients; line, median; box, 2575th percentile; whiskers, 2.5th and 97.5th percentile expansion; Here, significantly (p < 0.05) correlated inhibitors were
shown (red dots: positively correlated; blue dots: negatively correlated). Note that cells with smaller AUC values are more sensitive to the tested drugs. Dasatinib is listed as the
most negatively correlated drug. Pearson correlation was performed, and genome-wide transcriptomes were included. Bonferroni-corrected significance cutoff of |z| > 5.83, repre-
senting a two-tailed distribution with family-wise error-rate a < 0.025 in each tail, was used.
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driven SCLC subtype is vulnerable to HDACis single treatment. Recent
studies also demonstrated the effective inhibition of SCLC with HDA-
Cis [29,44,45], which could be further enhanced through combined
chemotherapies in preclinical models [34,46]. In a non-randomizedphase 2 trial, pan-HDACi panobinostat monotherapy demonstrated
tumour shrinkage in 2 out of 19 previously treated SCLC patients.
However, the study was based on unselected SCLC patients and pre-
maturely closed because of a lack of activity, arguing the need for bio-
markers-guided stratification of HDACis for the treatment of SCLC
Fig. 5. A reciprocal interaction between Dasatinib and HDACis. A, Volcano plots showing the extent of correlation between cytotoxic effects (reflected by the area under the curve
[AUC] value) of drug compounds in the library and protein levels of YAP and TAZ. The protein data of YAP and TAZ were extracted from an independent protein array dataset
assayed on hundreds of cancer cell lines from the TCPA portal (https://tcpaportal.org/mclp/#/), which was then integrated with the drug sensitivity data (AUC values). Green dots
indicate the significantly negatively correlated genes while the red the positively correlated ones. Note that cells with smaller AUC values are more sensitive to the tested drugs.
Dasatinib is listed as the most negatively (sensitive) correlated drug, while Vorinostat is the most positively (resistant) correlated one. B, Schematic models showing the rationale of
combined HDACis and Dasatinib in both YAP-driven and non-YAP-driven tumours, particularly SCLC (small-cell lung cancer). C, Dose-response curves (A) and synergy analysis (B)
of three SCLC (small cell lung cancer) cells treated for 96h with Dasatinib and Vorinostat (HDACi), alone or in combination. Data are shown as mean § s.d. (n=3). Fraction affected
(Fa) and combination index (CI) were determined by the CompuSyn software. CI < 1 indicates synergism. D, Clonogenic assay of SCLC cells (50000 cells/6-well) treated with Dasati-
nib and Vorinostat (HDACi), alone or in combination at the indicated drug concentrations for 7-14 days, depending on the doubling time of each cell line. Cells in the vehicle groups
were stained immediately once reaching confluence, and cells in the treated groups were stained several days later.
10 H. Yang et al. / EBioMedicine 69 (2021) 103457patients. Typically, SCLC is largely divided into 4 molecular subtypes:
ASCL1, NEUROD1, YAP1, and POU2F3 [8]. Intriguingly, in this study,
we found that YAP1 was the only subtyped SCLC highly correlated
with HDACi sensitive (negatively) and resistant (positively) signa-
tures (Fig. 2F; Suppl. Figure 1B), suggesting that HDACi as monother-
apy preferentially inhibits non-YAP1-featured SCLC subtype. Rewired
YAP activation, which is extensively involved in various therapy
resistance [47,48], might mediate the resistance to HDACis in SCLC or
other solid tumours.
Additionally, genes in the established HDACis resistant signature
are significantly enriched with the immune system (Fig. 5B). Sup-
porting our findings, emerging evidence has shown the role of HDACs
in modulating tumour immunity and efficacy to ICB [41,49-51]. In
contrast to genetic alterations, epigenetic plasticity enables rapid,
dynamic, and flexible changes that favour immune escape, and resis-
tance to therapies [52,53]. Therefore, targeting epigenetic alterationsrepresents a promising therapeutic approach and epigenetic-based
therapies could have a major clinical impact, notably in combination
with conventional therapies and immune therapies [54].
Thus, defining common HDACis response signatures provides
additional insights that allow for more effective and precise manage-
ment of HDAC inhibitors.
4.2. Combined targeted therapy with HDACis
As single agents, treatment with HDAC inhibitors has demon-
strated limited clinical benefit for patients with solid tumours,
prompting the investigation of novel treatment combinations with
other cancer therapeutics [7]. Treatment strategies combining HDA-
Cis with approved anticancer drugs could dramatically improve the
therapeutic success rate through inhibition of the tumour resistance
mechanism. The rationales of therapeutic combinations with HDAC
Fig. 6. The effects of combined HDACi and Dasatinib on SCLC cells. A, Flow cytometry-based analyses of apoptosis (Annexin V positive cells; left) and lipid reactive oxygen species
(ROS; right) assayed on SCLC cells (GLC-15) treated for 48h with Dasatinib (0.5 mM) and Vorinostat (HDACi; 1 mM), alone or in combination. The corresponding quantifications
(n=3) were shown on the right. *p < 0.05, **p < 0.01, ****p < 0.0001 by ANOVA test. NS, non-significance. B, Smallcell lung cancer (SCLC) cells (GLC-15) were treated for 72h with
combined Vorinostat (HDACi; 1 mM) and Dasatinib (0.5 mM) with or without 2.5 mM N-acetyl-L-cysteine (NAC). Cells were seeded 1,000 cells per well in 96-well plates. ****p <
0.0001 (n=3) by ANOVA test. NS, non-significance. C, Flow cytometry-based analyses of apoptosis (Annexin V positive cells; left) and lipid reactive oxygen species (ROS; right)
assayed on SCLC cells (GLC-15) treated for 24h with Dasatinib (0.5mM) and Vorinostat (HDACi; 1mM), alone or in combination. The assay was repeated twice.
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damaging chemotherapeutic agents, radiotherapy, hormonal thera-
pies, DNA methyltransferase inhibitors, and immunotherapies, as
well as various other small-molecule inhibitors [39,40,55-58].
Additionally, we and other groups have recently demonstrated
that Dasatinib treatment modulates host anti-tumour immunity, and
enhance the efficacy of immune checkpoint blockade (ICBs)
[28,59,60]. Intriguingly, functional pathway analysis of genes in the
HDACi resistant signature revealed enrichment of the immunity-
mediated pathways (Suppl. Figure 7A, 7B). Moreover, LGG tumours
(high HDACi sensitive signature) display a dramatic difference in the
immune subtypes, mainly immunologically quiet and lymphocyte
depleted subtypes, compared with MESO (high HDACi resistant sig-
nature) (Suppl. Figure 7C). In support of this, previous evidence also
showed the potential of HDACi to boost the effect of immunotherapy
[50]. Notably, these genes were also significantly enriched with a ref-
erence publication about the predictive biomarkers for Dasatinib
treatment in melanoma (Suppl. Figure 7B) [61]. Together, these anal-
yses further support an interplay between HDACi and Dasatinib treat-
ment and provide the rationale for combined HDACi and Dasatinib
targeted therapies.
In a recent phase III trial for advanced hormone receptor-positive
breast cancer, the HDAC inhibitor Chidamide in combination with
exemestane, increased the median progression-free survival to 7.4
months in comparison to 3.8 months with placebo [62], leading tothe approval of this combination for the treatment of breast cancer.
Other HDAC inhibitors are undergoing trials in solid tumours, includ-
ing entinostat in phase III trials for locally advanced or metastatic
recurrent hormone receptor-positive breast cancer (NCT02115282).
In this study, we found that Dasatinib together with HDACis might be
an ideal combined targeted therapy for certain solid tumours. First,
genes in the HDACis resistant signature whose high expression were
mostly correlated with the sensitivity profile of Dasatinib. Second,
high expression of YAP1 displays a strongly positive correlation with
HDACis resistant signature (Fig. 2H), and predict resistance to HDACis
but sensitivity to Dasatinib (Fig. 5A) [28]. Finally, Dasatinib syner-
gizes with HDACis in inhibiting SCLC cells (Fig. 5C-E). In line with our
findings, previous studies showed a synergistic treatment effect
between HDACis and imatinib, another clinically-approved BCR/ABL-
SRC inhibitor as Dasatinib, in leukaemia patients [15,63]. Also, a pre-
vious study showed that targeting HDAC could dramatically enhance
the efficacy of Dasatinib on pancreatic cancer cells [16]. Together,
combined Dasatinib and HDACi represent a promising combination
treatment in solid tumours, in particular in SCLC which is character-
ized by the highest HDACi sensitivity signature score across different
cancer types. Of note, although SCLC generally has the highest HDACi
sensitivity signature score, heterogeneity also exists, in that among
the four molecular subtypes of SCLC, YAP-driven SCLC is associated
with resistance to HDACi treatment alone. Given that Dasatinib treat-
ment could preferentially inhibit SCLC with YAP activation [10-13],
Fig.7. Dasatinib enhances antitumor effects of Vorinostat in preclinical SCLC mouse
models. A, Volumes of GLC15 xenografts treated with vehicle or the indicated drugs.
**p<0.01, ***p<0.001 by two-way ANOVA. B, Tumor weights at the end of the treat-
ment. Representative images of tumour size in each group were shown to the right.
*p<0.05 by one-way ANOVA.
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treatment for SCLC, independent of the four molecular subtypes.4.3. Potential molecular mechanisms underpinning the synergism
between combined SRC/Abl targeted therapies with HDACis
Despite the therapeutic efficacy of HDAC inhibition for certain
tumour subtypes, it remains unclear about the underlying molecular
mechanisms underpinnings the activities of HDAC inhibitors. Since
the main functions of HDAC are involved in the process of histone
deacetylation, altered chromatin remodelling activities or resulting
chromatin mark changes might play a role. Recent evidence showed
that the most prevalent changes associated with transcriptional regu-
lation caused by HDACi occur at distal enhancer elements [64-66].
Accordingly, accumulated evidence reveals that HDACi modulates
chromatin mark changes of acetylated H3K27 (H3K27ac) [64,66], a
typical marker of super-enhancers [67]. Consequently, HDACi
increases the acetylation level of the targeted genes, resulting in
enhanced gene transcription. Based on the importance of HDAC in
regulating super-enhancers, it is likely that the potential mechanisms
of the synergism between Dasatinib and HDACi might be due to the
upregulated activity of genes participating in the SRC-signalling
pathway, which is the main target of Dasatinib. Further studies are
warranted.
Overall, the use of surrogate biomarkers to predict the HDACis
therapy response is essential. Identification of subsets that are suit-
able for HDACis, and rational combinations, particularly with clini-
cally-approved inhibitors, that would lead to increased efficacy while
overcoming resistance will ensure the optimal clinical application of
these agents. Pharmacogenomics enables robust identification of
molecular signatures that may help to predict HDACi therapeutic
response and cancer subtypes that are suitable for HDACi treatment.
Dasatinib is a synergistic combination to enhance HDAC-targeted
therapy in SCLC.Contributors
Conceptualisation: H.Y. and F.Y.; Data curation: Y.H., K.X. and T.Z.;
Formal analysis: H.Y. and B.S.; Investigation: H.Y., B.S., Y.H., K.X. and
T.Z. This study was conceived, designed, and interpreted by H.Y., and
F.Y., H.Y., B.S.; Methodology: H.Y.; Project administration: F.Y. and
G.H.; Software: H.Y.; Supervision: F.Y. and G.H.; Writing  original
draft: H.Y.; S.R.R.H. critically reviewed the manuscript; H.Y., F.Y. and
G.H. had primary responsibility for the final content; All authors read,
revised and approved the final manuscript.
Funding
This work was supported by the National Natural Science Founda-
tion of China (82072570 to F. Yao; 82002941 to B. Sun).
Declaration of Competing Interest
The authors declare that they have no conflict of interest.
Acknowledgements
We thank Haizhen Jin (Central Laboratory, Shanghai Chest Hospi-
tal, Shanghai Jiao Tong University) for the flow cytometry analysis.
This study used TCGA Program database. The interpretation and
reporting of these data are the sole responsibility of the authors. The
authors acknowledge the efforts of the National Cancer Institute. This
work was supported by the National Natural Science Foundation of




Supplementary material associated with this article can be found
in the online version at doi:10.1016/j.ebiom.2021.103457.
References
[1] Verza FA, Das U, Fachin AL, Dimmock JR, Marins M. Roles of Histone Deacetylases
and Inhibitors in Anticancer Therapy. Cancers (Basel) 2020;12(6).
[2] Nalawansha DA, Zhang Y, Herath K, Pflum MKH. HDAC1 Substrate Profiling Using
Proteomics-Based Substrate Trapping. ACS Chem Biol 2018;13(12):3315–24.
[3] Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetyla-
tion as cancer therapy targets. Expert Rev Anticancer Ther 2010;10(6):935–54.
[4] Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, et al. Histone
deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm 2011;8
(6):2021–31.
[5] Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as
Anticancer Drugs. Int J Mol Sci 2017;18(7).
[6] Weichert W. HDAC expression and clinical prognosis in human malignancies.
Cancer Lett 2009;280(2):168–76.
[7] Ho TCS, Chan AHY, Ganesan A. Thirty Years of HDAC Inhibitors: 2020 Insight and
Hindsight. J Med Chem 2020;63(21):12460–84.
[8] Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D, et al. The
Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer
cells. Oncogene 2019;38(42):6801–17.
[9] Basu D, Reyes-Mugica M, Rebbaa A. Histone acetylation-mediated regulation of
the Hippo pathway. PLoS One 2013;8(5):e62478.
[10] Sun J, Wang X, Tang B, Liu H, Zhang M, Wang Y, et al. A tightly controlled Src-YAP
signaling axis determines therapeutic response to dasatinib in renal cell carci-
noma. Theranostics 2018;8(12):3256–67.
[11] Yang H, Xu D, Schmid RA, Peng RW. Biomarker-guided targeted and immuno-
therapies in malignant pleural mesothelioma. Ther Adv Med Oncol
2020;12:1758835920971421.
[12] Yang H, Zhao L, Gao Y, Yao F, Marti TM, Schmid RA, et al. Pharmacotranscriptomic
Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Can-
cer. Cancers (Basel) 2020;12(11).
[13] Lamar JM, Xiao Y, Norton E, Jiang ZG, Gerhard GM, Kooner S, et al. SRC tyrosine
kinase activates the YAP/TAZ axis and thereby drives tumor growth and metasta-
sis. J Biol Chem 2019;294(7):2302–17.
H. Yang et al. / EBioMedicine 69 (2021) 103457 13[14] Rauzan M, Chuah CT, Ko TK, Ong ST. The HDAC inhibitor SB939 overcomes resis-
tance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism
in chronic myeloid leukemia. PLoS One 2017;12(3):e0174107.
[15] Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, et al. HDAC inhibitors
potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sen-
sitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res
2011;17(10):3219–32.
[16] Chien W, Sudo M, Ding LW, Sun QY, Wuensche P, Lee KL, et al. Functional
Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic
Cancer Cells to Dasatinib. J Cancer 2018;9(24):4762–73.
[17] Chou TC. Drug combination studies and their synergy quantification using the
Chou-Talalay method. Cancer Res 2010;70(2):440–6.
[18] Yang H, Liang SQ, Xu D, Yang Z, Marti TM, Gao Y, et al. HSP90/AXL/eIF4E-regulated
unfolded protein response as an acquired vulnerability in drug-resistant KRAS-
mutant lung cancer. Oncogenesis 2019;8(9):45.
[19] Xu D, Yang H, Yang Z, Berezowska S, Gao Y, Liang SQ, et al. Endoplasmic Reticu-
lum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.
Cancers (Basel) 2019;11(10).
[20] Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, et al. CRISPR Screen-
ing Identifies WEE1 as a Combination Target for Standard Chemotherapy in
Malignant Pleural Mesothelioma. Mol Cancer Ther 2020;19(2):661–72.
[21] Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, et al. Correlat-
ing chemical sensitivity and basal gene expression reveals mechanism of action.
Nat Chem Biol 2016;12(2):109–16.
[22] Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An interactive
resource to identify cancer genetic and lineage dependencies targeted by small
molecules. Cell 2013;154(5):1151–61.
[23] Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al.
Regulation of ferroptotic cancer cell death by GPX4. Cell 2014;156(1-2):317–31.
[24] Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, et al. TCPA: a resource for cancer func-
tional proteomics data. Nat Methods 2013;10(11):1046–7.
[25] Tlemsani C, Pongor L, Elloumi F, Girard L, Huffman KE, Roper N, et al. SCLC-Cell-
Miner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacol-
ogy Based on Genomic Signatures. Cell Rep 2020;33(3):108296.
[26] Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The
Immune Landscape of. Cancer. Immunity. 2018;48(4):812–30 e14.
[27] Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, et al. Comprehensive Molec-
ular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep 2018;25
(5):1304–17 e5.
[28] Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid RA, et al. Systematic Analysis of Aber-
rant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor
Suppressor Loss in Malignant Pleural Mesothelioma. Cancers (Basel), 12; 2020.
2020.
[29] Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, et al.
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung can-
cer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol
Cancer Ther 2009;8(8):2221–31.
[30] Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular sub-
types of small cell lung cancer: a synthesis of human and mouse model data. Nat
Rev Cancer 2019;19(5):289–97.
[31] Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM,
et al. Thalidomide versus active supportive care for maintenance in patients with
malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label,
multicentre, randomised phase 3 study. Lancet Oncol 2013;14(6):543–51.
[32] Zhang C, Moore LM, Li X, Yung WK, Zhang W. IDH1/2 mutations target a key hall-
mark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol
2013;15(9):1114–26.
[33] Sears TK, Woolard KD. Abstract 1917: The HDAC inhibitor panobinostat elicits
preferential cytotoxic and antiproliferative effects in IDH mutant glioblastoma.
Cancer Research 2020;80(16 Supplement):1917. -.
[34] Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic
antitumor effect between vorinostat and topotecan in small cell lung cancer cells
is mediated by generation of reactive oxygen species and DNA damage-induced
apoptosis. 2009;8(11):3075-87.
[35] Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, et al.
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Poten-
tial. Cell 2018;173(6):1413–25 e14.
[36] McClure JJ, Li X, Chou CJ. Advances and Challenges of HDAC Inhibitors in Cancer
Therapeutics. Adv Cancer Res 2018;138:183–211.
[37] Mrakovcic M, Frohlich LF. Molecular Determinants of Cancer Therapy Resistance
to HDAC Inhibitor-Induced Autophagy. Cancers (Basel) 2019;12(1).
[38] Rana Z, Diermeier S, Hanif M, Rosengren RJ. Understanding Failure and Improving
Treatment Using HDAC Inhibitors for Prostate Cancer. Biomedicines 2020;8(2).
[39] Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors
and their therapeutic implications. Clin Cancer Res 2007;13(24):7237–42.
[40] Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer
Res 2009;15(12):3970–7.
[41] Zhao LM, Zhang JH. Histone Deacetylase Inhibitors in Tumor Immunotherapy.
Curr Med Chem 2019;26(17):2990–3008.[42] Zhang X, Wang X, Wang XQD, Su J, Putluri N, Zhou T, et al. Dnmt3a loss and Idh2
neomorphic mutations mutually potentiate malignant hematopoiesis. Blood
2020;135(11):845–56.
[43] Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z, et al. The application of histone
deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res 2020;39(1):138.
[44] Jia D, Augert A, Kim DW, Eastwood E, Wu N, Ibrahim AH, et al. Crebbp Loss Drives
Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Dis-
cov 2018;8(11):1422–37.
[45] Sun L, He Q, Tsai C, Lei J, Chen J, Vienna Makcey L, et al. HDAC inhibitors sup-
pressed small cell lung cancer cell growth and enhanced the suppressive effects
of receptor-targeting cytotoxins via upregulating somatostatin receptor II. Am J
Transl Res 2018;10(2):545–53.
[46] Pan CH, Chang YF, Lee MS, Wen BC, Ko JC, Liang SK, et al. Vorinostat enhances the
cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer
2016;16(1):857.
[47] Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev
Cancer 2013;13(4):246–57.
[48] Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al. A YAP/
FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased
expression of spindle assembly checkpoint components. Sci Transl Med 2020;12
(559).
[49] Bretz AC, Parnitzke U, Kronthaler K, Dreker T, Bartz R, Hermann F, et al. Domati-
nostat favors the immunotherapy response by modulating the tumor immune
microenvironment (TIME). J Immunother Cancer 2019;7(1):294.
[50] Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC
inhibitors and immunotherapy; a double edged sword? Oncotarget 2014;5
(16):6558–72.
[51] Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. HDAC inhibitors
overcome immunotherapy resistance in B-cell lymphoma. Protein Cell 2020;11
(7):472–82.
[52] Aspeslagh S, Morel D, Soria JC, Postel-Vinay S. Epigenetic modifiers as new immu-
nomodulatory therapies in solid tumours. Ann Oncol 2018;29(4):812–24.
[53] Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of
cancer. Science 2017;357(6348).
[54] Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev
Genet 2016;17(10):630–41.
[55] Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies.
Adv Cancer Res 2012;116:199–237.
[56] Huan S, Gui T, Xu Q, Zhuang S, Li Z, Shi Y, et al. Combination BET Family Protein
and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis
Through RAD51-Related DNA Damage Repair. Cancer Manag Res 2020;12:4429–
39.
[57] Miyamoto K, Watanabe M, Boku S, Sukeno M, Morita M, Kondo H, et al. xCT Inhi-
bition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner. Cancers
(Basel) 2020;12(4).
[58] Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, et al. Targeting histone deace-
tylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR
-activating mutant lung adenocarcinoma. Translational Lung Cancer Research
2021;10(4):1857–72.
[59] Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, et al. Targeting
DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci Adv 2019;5(2):
eaav2437.
[60] Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, et al. Evolution of genomic and T
cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib
treatment. Clin Cancer Res 2020.
[61] Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, et al.
Predictive biomarkers for dasatinib treatment in melanoma. Oncoscience 2014;1
(2):158–66.
[62] Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, et al. Tucidinostat plus exemestane for
postmenopausal patients with advanced, hormone receptor-positive breast can-
cer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol 2019;20(6):806–15.
[63] Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gerard D, et al.
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid
leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resis-
tance and stem cells. Clin Epigenetics 2020;12(1):69.
[64] Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, et al. HDAC inhibitors elicit
metabolic reprogramming by targeting super-enhancers in glioblastoma models.
J Clin Invest 2020;130(7):3699–716.
[65] Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, et al. Transcriptional
Dependencies in Diffuse Intrinsic Pontine Glioma. Cancer Cell 2017;31(5):635–52
e6.
[66] Sanchez GJ, Richmond PA, Bunker EN, Karman SS, Azofeifa J, Garnett AT, et al.
Genome-wide dose-dependent inhibition of histone deacetylases studies reveal
their roles in enhancer remodeling and suppression of oncogenic super-
enhancers. Nucleic Acids Res 2018;46(4):1756–76.
[67] Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al.
Histone H3K27ac separates active from poised enhancers and predicts develop-
mental state. Proc Natl Acad Sci U S A. 2010;107(50):21931–6.
